In contrast to the other RUNX family members such as RUNX1 and RUNX3 whose mutations are tightly linked to the promotion of leukemia and gastric cancer, respectively [116, 117], the initial studies strongly suggest that RUNX2 acts as a master regulator of osteoblast differentiation and bone development. This evidence concerns the gene RUNX3 and gastric cancer.